Evidence map›Paper›PMID 39384614›Full record

ArticleJournal of perinatology : official journal of the California Perinatal Association2025

Outcomes after intranasal human milk therapy in preterm infants with intraventricular hemorrhage.

Alessia Gallipoli, Sharon Unger, Amr El Shahed, Chun-Po Steve Fan, Marisa Signorile, Diane Wilson, Rebecca Hoban

Registry-linked trialAbstract readClinical Trial, Phase IMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of perinatology : official journal of the California Perinatal Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04225286 (Intranasal Human Milk as Stem Cell Therapy in Preterm Infants With Intraventricular Hemorrhage), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04225286 naunknown statusnot on this map

Intranasal Human Milk as Stem Cell Therapy in Preterm Infants With Intraventricular Hemorrhage

TypeinterventionalSponsorThe Hospital for Sick ChildrenRan2020 to 2023Enrolled37ConditionsIntraventricular HemorrhageArmsHuman breast milk
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Perinatal Neuroprotection in Preterm Birth.Geburtshilfe und Frauenheilkunde · 2025
    Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alessia GallipoliDivision of Neonatology, The Hospital for Sick Children, Toronto, ON, Canada.
Sharon UngerDepartment of Paediatrics, Izaak Walton Killam Hospital, Halifax, NS, Canada.ORCID 0000-0001-8091-5742
Amr El ShahedDivision of Neonatology, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0002-5898-1927
Chun-Po Steve FanTed Rogers Computational Program, Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-1278-0118
Marisa SignorileTed Rogers Computational Program, Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada.
Diane WilsonDivision of Neonatology, The Hospital for Sick Children, Toronto, ON, Canada.
Rebecca HobanDivision of Neonatology, The Hospital for Sick Children, Toronto, ON, Canada. rebecca.hoban@seattlechildrens.org.ORCID 0000-0001-9457-8791

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIntraventricular hemorrhage (IVH) is a common cause of brain injury in preterm infants. Fresh human milk (HM) contains stem cells (SCs) that could potentially be delivered via intranasal HM (IHM). In this IHM pilot study, we describe outcomes. STUDY

designInfants <33 weeks gestation with IVH were given IHM until maximum 28 days of age. Short-term neurologic outcomes and follow-up testing were compared to historic HM-fed infants. Longitudinal outcomes were plotted using linear mixed models. Weighted G-computation quantified treatment effects. Propensity score models calculated inverse probability weights for IVH grade, gestational age, and sex.

result37 infants (35.1% grade 3-4 IVH) were compared to 191 historic controls (17.8% grade 3-4 IVH). Post-hemorrhagic ventricular dilatation was common (25.7% IHM patients). Most weighted outcomes, although not significant, favored IHM at 4-12 and 18 months corrected age.

conclusionThis phase 1 study suggests powered trials of IHM for brain injury are needed. CLINICAL TRIAL REGISTRY NAME: clinicaltrials.gov identifier NCT04225286.

Indexed as

Cerebral HemorrhageCerebral Intraventricular HemorrhageInfant, Premature, DiseasesMilk, HumanAdministration, IntranasalFemaleGestational AgeHumansInfantInfant, NewbornInfant, PrematureMalePilot ProjectsTreatment Outcome

Identifiers

PMID39384614

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.